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Cancer is a complex and adaptable disease, and knowledge of the mechanisms that 
cause its progression is vital to creating and monitoring anti-cancer therapies.  As a tumor 
grows beyond a few mm
3
, blood vessels are recruited to provide additional nutrients in a 
process called angiogenesis.  Some novel drug therapies specifically target this process, 
and the efficacy of these drugs can in principle be monitored by a technique called 
angiography.  3D angiography, a method of imaging the vasculature, can be performed 
by several imaging modalities typically with the use of a contrast agent.   
A technique is introduced which uses high resolution ultrasound in conjunction with 
an ultrasound contrast agent to produce 3D images of the vasculature. This method offers 
a faster, more accessible, and cheaper alternative to assess the efficacy of anti-angiogenic 
drugs in preclinical cancer models.  In addition to vessel imaging, modeling the kinetic 
behavior of the contrast agent in the vasculature can elucidate parameters such as blood 
flow, which can also serve as an indicator of drug treatment efficacy.  The repeatability 
of a commonly used mono-exponential model is assessed in order to determine thresholds 
for inter/intra-subject error. 
 ii 
The 3D vessel imaging technique presented in this thesis correlated with other 
measures of blood flow (r = 0.55 ± 0.04, p < 0.01) and shows an increased sensitivity to 
microvasculature within tumors.  Also, preliminary repeatability analysis (n = 6) on the 
modeling parameter which is proportional to contrast agent velocity shows a mean 
difference of 0.061 ± 0.298 between independent measurements, and the limits of 
agreement range from -0.536 and 0.656.  The developments exhibited provide additional 
methods for monitoring longitudinal anti-angiogenic cancer treatments in preclinical 
models. 
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CHAPTER I 
 
INTRODUCTION 
 
Cancer and Angiogenesis 
While no single definition can characterize all forms of cancer, for the sake of 
simplicity, a usefule general definition of cancer is "a set of diseases characterized by 
unregulated cell growth leading to invasion of surrounding tissues and spread 
(metastasis) to other parts of the body" [1].  This definition is insufficient due to the many 
different types of cancers in existence (e.g., lung, breast, pancreas, skin melanoma, etc) 
that all express varying attributes that govern growth rate, metastatic state, and lethality.  
While prevention is the best defense against cancer, understanding the mechanisms 
responsible for the behaviors of various cancers can elucidate methods of early detection 
and treatment. 
One specific characteristic of cancer that has been exploited for monitoring tumor 
growth and treatment response is angiogenesis.  Angiogenesis is the recruitment of blood 
vessels by the primary cancer site in order to provide additional nutrients.  As the tumor 
grows beyond approximately one mm
3
, diffusion can no longer provide essential 
nutrients for the tumor cells thus creating hypoxic regions.  Growth factors such as 
platelet-derived growth factor, fibroblast growth factor (FGF), and vascular endothelial 
growth factor (VEGF) are then secreted to promote the migration of endothelial cells to 
the site through a chemotactic response to the growth factor concentration [1].  However, 
the vessels produced differ from normal vasculature; the vessels are typically tortuous, 
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leaky, and poorly constructed.  Thus, monitoring angiogenesis provides insight into 
tumor growth and anti-angiogenic treatment response [2-3].     
 
Angiography 
Imaging can provide a non-invasive means for examining the tumor 
microenvironment for both pre-clinical and clinical applications.  Biopsies are invasive 
and challenging during longitudinal studies of cancer.  Imaging provides non-invasive in 
vivo monitoring of the progression, growth and functionality of the cancer.  Different 
imaging modalities provide methods of measuring angiogenesis in vivo; angiography, or 
the mapping of vasculature, is typically accomplished by the use of an exogenous 
contrast agent.  In magnetic resonance imaging (MRI), a paramagnetic agent, such as 
gadolinium, is injected into the blood stream.   The agent changes the relaxation time of 
the surrounding tissue and thereby affects the tissue contrast.  In computed tomography 
(CT), iodine based contrast agent is typically used because of its ability to attenuate more 
X-rays than the surround tissue.  However, these modalities have both strengths and 
weaknesses.  While MRI uses non-ionizing radiation, the process can be time-consuming 
and costly.  CT requires a dose of radiation for every visit so longitudinal studies are 
limited.  This thesis presents a safe, cost-effective, and time-saving alternative to these 
methods using contrast enhanced ultrasound (CEUS) as a method for high resolution 3D 
vessel imaging in small animal models of cancer. 
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Ultrasound 
Ultrasound imaging exploits the acoustic properties of tissue.  The technique utilizes 
a transducer that transforms electrical energy into mechanical energy to produce a sound 
wave that can propagate through a medium (tissue).  This longitudinal wave will cause 
elements of the medium to vibrate at individual velocities (u(x,t)).  For a planar wave, the 
ratio of the acoustic pressure and the particle velocity (u(x,t)) is the acoustic impedance 
(Z) a characteristric of the medium.  As the waves continue through the tissue, the energy 
can be absorbed, scattered or reflected back to the source.  The sound wave obeys Snell’s 
Law of Refraction: 
                Z1sin(θ1) = Z2sin(θ2)     (Equation 1) 
where θ is the angle of incidence of the first medium and the angle of refraction within 
the second medium, and Z1 and Z2 are the acoustic impedances of the first and second 
media, respectively.  The intensity of the reflected wave (R) at normal incidence depends 
on the change in Z of the tissue and incident intensity (I): 
    I
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.       (Equation 2) 
The acoustic impedance depends on the density and elastic stiffness of the medium and 
varies between different biological tissues.  Consequently, changes in Z produce 
backscattered ultrasound (echoes), and they are the basis of the contrast seen in 
ultrasound images. 
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Ultrasound Contrast Agents (UCAs) 
According to Equation 2, the larger the difference in impedance between two sections 
of tissue, the more reflection occurs at the interface between those two media.  UCAs are 
composed of air or high density gas surrounded by a stabilization shell [4-8] yielding an 
acoustic impedance value of approximately 0.0004 x 10
6
 rayls while the Z value for 
blood is 1.65 x 10
6
 rayls [9].   Delivering UCAs into the bloodstream creates a significant 
reflected signal that can indicate spatial information about where the contrast agent is 
distributed.  As acoustic energy is deposited, the UCA begin to expand and contract at a 
certain frequency.  The natural frequency or resonance frequency ( 0f ), at which the 
bubble oscillates is related to its radius (r): 
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f =       (Equation 3) 
where P0 is ambient fluid pressure, γ is the adiabatic ideal gas constant, and 0ρ  is 
ambient fluid density [10].   
For microbubbles with sizes less than 10 µm, the natural frequency falls within the 
diagnostic ultrasound range of 1 – 20 MHz.  The increased reflectance of the resonating 
UCA is due to the expansion (followed by a contraction) of the bubble size.  As shown in 
Figure 1, at low power input, the microbubbles behave in a linear fashion, resonating at 
the natural frequency.  However, at higher power input, the contrast agent begins to 
demonstrate nonlinear resonance, producing harmonics of the natural frequency [10].  At 
even higher power, the bubbles can be destroyed by extreme expansion and contraction, 
which can be advantageous in some applications. 
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Kinetic Modeling of Ultrasound Contrast Agents 
In order to provide quantitative measurements with UCAs, two main assumptions are 
required.  The first assumption requires that the UCA do not have a hemodynamic effect 
(i.e., no influence on blood flow or circulation) [12-13], and secondly, the UCAs are 
assumed to remain in constant flow and are not metabolized in any way [14]. With these 
assumptions, mathematical models have been produced to assess such properties as tissue 
blood flow, vascular integrity, branching pattern, and density using UCA [11,15-17].   
Since UCAs can be destroyed at a high mechanical index (M.I.), imaging reperfusion 
of an area allows for repeated measurements of the contrast dynamics.  After a certain 
time following a contrast agent infusion, the concentration of contrast reaches a steady-
state within the blood.  By destroying the microbubbles in a section of vasculature, the 
 
Figure 1. Microbubble behavior changes as a function acoustic power.  As the 
mechanical index (MI) increases, the microbubbles oscillate at different frequencies until 
disruption [11].   
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replenishment of contrast agent can reflect cross sectional area, UCA velocity, and blood 
flow [17].  Plotting the time course before, during and after a bolus of contrast is injected 
or destruction sequence yields a time intensity curve (TIC) such as in Figure 2.   
 
 
 
This TIC can be described mathematically by examining the shape of the curve produced 
with the following equation: 
     )]exp(1[)( tBtVI ⋅−−⋅= β ,   (Equation 4) 
where VI(t) is backscattered intensity at time t, B is the asymptotic plateau, and β is the 
rate of replenishment  of microbubble concentration. For each pixel within an ultrasound 
image, the intensity changes based on the concentration of the agent present [12,18].  The 
curve is fit to Equation 4 which provides parameters of B and β, estimates of vessel 
cross-sectional area and UCA velocity, respectively.  The product of these two 
parameters provides an estimate of blood flow. 
 
Figure 2. Panel a represents a time intensity curve produced from the region of interest 
(ROI) selected in panel b. Panel b is a B-mode image of a subcutaneous tumor in a 
mouse. The green overlay indicates the increased signal intensity from UCA.  The signal 
intensity increases mono-exponentially as the UCA enters the field. 
a b 
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CHAPTER II 
 
DEVELOPMENT OF HIGH RESOLUTION CONTRAST ENHANCED  
VESSEL IMAGING USING ULTRASOUND 
 
Introduction 
Non-invasive imaging methods that can quantitatively evaluate tumor 
microvasculature in pre-clinical models of cancer can provide valuable information on 
both tumor growth and treatment response.  In particular, treatments that affect the 
vasculature of a tumor (e.g., anti-angiogenic drugs) can be monitored using vessel 
imaging techniques. Several imaging modalities can be used to generate 3D angiograms 
for monitoring vessel distribution and anti-angiogenic treatment effects, and each 
modality has both strengths and weakness.  While CT techniques can approach 
resolutions on the order of 50 µm, each scan requires the use of ionizing radiation and 
injections of relatively large volumes (300-400 µL in mice) of contrast agent, thereby 
limiting the number of repeat studies that can be performed.  Magnetic resonance 
angiography (MRA) requires no ionizing radiation and provides a spatial resolution of 
approximately 80 µm in reasonable time [19], but the technique is costly, time 
consuming, and not always reliable in the presence of physiological motion. Ultrasound 
methods have been proposed for vessel imaging by exploiting the Doppler effect. 
Changes in the frequency of the ultrasound signal caused by the movement of the flowing 
blood through static tissue allow Doppler ultrasound techniques to isolate vasculature.  
However, this type of analysis is known to have significant user-dependence.  In 
particular, if the angle of the imaging plane is not perpendicular to the vessel, a true 
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cross-section of the vessel may not be measured thereby introducing significant errors 
[20]. Here we report our experience in imaging tumor vasculature using an alternative 
approach based on ultrasound contrast agents.  UCAs provide a highly sensitive method 
of imaging microvasculature at the capillary level without the limitations of the above 
mentioned techniques [20]. 
 As previously mentioned, UCAs are an intravascular contrast agent and can 
produce replenishment (wash-in) curves repeatedly during a single scan to characterize 
parameters such as blood flow in a particular area of interest [17]. These replenishment 
curves are time courses that characterize the intensity of the contrast produced as agent 
flows into a region of tissue and can be repeated by taking advantage of microbubble 
behavior under high power. By utilizing these characteristics, UCAs are attractive 
candidates for developing ultrasound contrast enhanced vessel imaging (CEVI), and their 
kinetic behavior can provide boundary parameters for the development of such a 
technique.   
 Once the UCAs are destroyed in a slice, the contrast agent reperfuses the region 
of interest.  The image gathered immediately after the destruction pulse, which contains 
no contrast agent, can be subtracted from a later image that contains UCA to create an 
image that represents only the contrast enhanced vasculature.  A 3D image of the 
vasculature can be created by incrementing through the tumor and repeatedly imaging the 
destruction and replenishment cycle in each slice.  By examining how long the UCA 
remains in circulation as well as by obtaining the maximum number of destruction pulses 
that can be applied while maintaining significant enhancement, we develop a CEUS 
approach to generate high-resolution 3D images of tumor vasculature. 
 9 
 
Materials and Methods 
Data Acquisition 
 
Duration of UCA Enhancement 
All procedures adhered to our Institution’s Animal Care and Use Committee 
guidelines.  Eight female mice were injected subcutaneously with 10
6
 67NR breast cancer 
cells in the hind limb.  Eight days postinjection, they were imaged on a Visualsonics 
Vevo 770 (Toronto, Canada) system using a 40 MHz transducer mounted to a 3D motor 
on a rail system.  Two days prior to imaging, 26G jugular catheters were surgically 
implanted for delivery of the contrast agent. During the imaging session, the animals 
were anesthetized with a 2%/98% isoflurane/oxygen mixture, and body temperature was 
monitored and maintained at 37
o
 C by a warming plate.  Heart rate was also monitored 
and remained approximately 350 – 400 bpm.   
Coupling gel was applied to the area of interest, and 2D B-mode and power Doppler 
scout images established a slice of tumor with vascularity present.  The field of view 
varied from 9 mm X 9 mm to 12 mm X 12 mm depending on tumor size, establishing an 
in plane pixel size of less than or equal to ~25 µm X 25 µm.  Image acquisition began 
immediately prior to a 50 µl bolus of Visualsonics Micromarker UCA (1.0 x 10
8
 
microbubbles/50 µL injection) injected via a jugular catheter.  This UCA is specifically 
designed for high frequency (30 – 45 MHz) ultrasound imaging, and the diameter of the 
microbubbles range from 2 to 3 µm.  Images were obtained within Visualsonics Contrast 
mode at a frame rate of 6-8 frames/second at 50% power (mechanical index (M.I.) of 
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0.14) for 10 minutes with no respiratory gating. This process was repeated for each 
mouse after 30 minutes which allowed for the clearance of any residual contrast [21]. 
Reperfusion repeatability 
Animal preparation and field of view were identical to the duration of UCA 
enhancement study.  Once the 50 µl bolus of Visualsonics Micromarker UCA injected 
reached steady state (approximately 45 seconds) [17,22], imaging began using the 
Visualsonics Contrast mode at a frame rate of 14 frames/second at 50% power. A 100% 
power destruction pulse (M.I. of 0.59) was administered, and images were collected for 
approximately 15-20 seconds in order to characterize the reperfusion curve.  Twelve to 
eighteen sets of reperfusion images were collected using multiple destruction pulses over 
the maximum time dictated by the duration of UCA enhancement study described above.  
This process was then repeated for each subject after a 30 minute period of time. 
3D CEVI 
Using the preparation described in the previous studies, B-mode scout images 
established the most posterior slice of the region of interest.  A 50 µl bolus of UCA was 
injected and allowed to reach equilibrium within the blood stream.  Imaging at 50% 
power began after equilibrium was reached, and a destruction pulse was administered, 
followed by 15-20 seconds of image acquisition with no respiratory gating.  Images were 
obtained within Visualsonics Contrast mode at a frame rate of 14 frames/second. The 
transducer was calibrated to fix on the next slice of tissue 330 µm in the anterior direction 
by manually incrementing a translation stage.  A destruction pulse was administered 
followed by another 15-20 seconds of image acquisition.  This process was repeated for 
each slice of tissue until the entire tumor was covered.  Additional (up to three) injections 
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of UCA were utilized based on the maximum number of destructions determined in the 
reperfusion repeatability study described above.   
3D power Doppler images were also obtained to compare the proposed vessel 
imaging method to an accepted ultrasound method of detecting flow.  Using the same 
field of view and step size as the CEVI technique, 3D power Doppler and B-mode images 
of the tumor were also collected.  Respiratory gating was used, and the power was set to 
100% with the scan speed of 2.0 mm/s. The wall filter was set to 2.5 mm/s to eliminate 
echoes from the vessel wall movement. 
 
Data Analysis 
 
Duration of UCA Enhancement 
Data analyses were performed using Visualsonics software, Microsoft Excel 2003 
(Redmond, WA, USA), and Matlab R2006a (The Mathworks, Natick, MA, USA).  ROIs 
of the entire tumor area were manually drawn, and the average intensity for each frame 
was computed in order to construct a time intensity curve for each mouse.   Eight sets of 
TICs, two injections for each subject (one set), were exported to Excel, and the minimum 
intensity value was subtracted from all points in the time course to eliminate baseline 
noise.  For each set, the TIC obtained from the first injection was plotted against the 
second injection TIC in order to assess the repeatability of the study.  Additionally, each 
TIC was exported to Matlab to determine the time during washout in which enhancement 
from the UCA is no longer above 20% of the baseline during imaging.   
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Reperfusion repeatability  
Data analyses were performed using Visualsonics software, Microsoft Excel 2003, 
and Matlab R2006a.  ROIs of the entire tumor area were manually drawn, and the 
average intensity for each frame was computed in order to form a TIC for each subject.   
The data were then exported to Matlab.  Each data segment containing a destruction pulse 
and subsequent reperfusion frames were separated into individual files, and the minimum 
intensity value was subtracted from all points in the time course.  Time course data were 
smoothed temporally by using a moving window filter with a window size of three. Each 
time course for an injection contained anywhere from 12 to 18 segments. 
 
3D CEVI 
Data analyses were performed using Matlab R2006a. The maximum duration for 
UCA image enhancement and the number of destruction pulses allowed before 
insignificant enhancement were determined from the two studies described above, and 
the results were applied to determine data acquisition boundary parameters for 3D CEVI.  
The data were then exported to Matlab, and each frame within a time course was 
downsampled to a 256 X 256 image matrix. Frames within a data set were co-registered 
to the baseline time course frame using a rigid-body algorithm to eliminate any motion 
artifacts [23-24].  The registration algorithm relies on mutual information shared between 
each image set.  A transformation is applied to the reference image that maximizes shared 
information with the target image file. The registered images were processed using a 
maximum intensity pixel (MIP) algorithm. The last slice was subtracted from the first 
post-destruction image to eliminate baseline intensity, and any pixel displaying intensity 
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less than 20% of the maximum was eliminated (i.e., set to zero intensity).  In addition, a 
maximum change in intensity map was created. The mean and standard deviation were 
found from an ROI containing rapidly enhancing voxels, which are characteristic of the 
presence of an UCA.  Any voxel below the mean of the ROI minus one standard 
deviation was not considered rapidly enhancing and was set to zero intensity.  Finally, the 
images were filtered for stray pixels that had less than three enhancing pixels surrounding 
the pixel being interrogated. The process was repeated for each slice within a volume.   
Processed CEVI slices and anatomical slices were fused into separate volume images. 
Anatomical volumes from the 3D CEVI region of interest were co-registered to 
anatomical volumes collected using the 3D power Doppler technique.  The 
transformation was applied to the power Doppler data thereby registering it with the 3D 
CEVI data.  Logical masks, where 1 represented vasculature signal and 0 represented no 
vasculature signal, were created for both the CEVI slice and the corresponding power 
Doppler slice in all data sets.  2D Pearson correlation coefficients for each slice were 
found using the corr2 command in Matlab. 
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Results 
 
Duration of UCA Enhancement 
Time course images were obtained for each injection at an in plane pixel size of ~25 
µm X 25 µm. ROIs were drawn and TICs were analyzed using this native resolution.   
Plots of the TIC were created in Excel, and visual inspection was used to predict the 
maximum clearance time of the UCA for the reperfusion repeatability study.  
 
TABLE 1 
Results from the Duration of UCA Enhancement Study 
Mouse Injection # Time (min) Slope r p-value 
1 3.80 
1 
2 4.20 
1.96 0.97 < 0.05 
1 4.20 
2 
2 5.60 
1.16 0.99 < 0.05 
1 3.60 
3 
2 4.50 
1.31 0.95 < 0.05 
1 5.30 
4 
2 4.70 
1.29 0.98 < 0.05 
1 4.10 
5 
2 5.30 
0.49 0.93 < 0.05 
1 4.80 
6 
2 3.90 
0.80 0.98 < 0.05 
1 1.90 
7 
2 3.20 
0.68 0.67 < 0.05 
1 3.30 
8 
2 6.60 
0.85 0.96 < 0.05 
 
Table 1 presents the time each injection took to return to approximately 20% above 
baseline level. Baseline levels were described to be the average intensity immediately 
prior to contrast uptake.  The mean time of UCA image enhancement was found to be 
4.30 minutes ±  of 1.09 minutes.  
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For each mouse, the TIC from injection one was plotted against the injection two TIC 
as demonstrated in Figure 3.   Data were cropped such that it included only the wash out 
from each injection because possible variation in injection rate introduced unstable wash-
in curves.   
 
 
 
Table 1 describes the slope and r-values corresponding to each set plotted. P-values for 
all sets of injections were computed using ANOVA and found to be less than 0.05 in all 
cases.  
 
Reperfusion repeatability 
Results were obtained from six mice; data from two mice were discarded due to 
errors in UCA injection; however, all eight mice were successfully used in the other 
studies described.  Images produced were the same in plane resolution as described 
above.  Time courses were exported to Excel to estimate the number of destructions 
 
Figure 3. Panel a demonstrates the entire pre- and post-injection TIC with the highlighted 
region that was compared in panel b. The linearity seen in panel b depicts the 
repeatability of the washout curve. 
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delivered before enhancement was insignificant.  Example TICs resulting from this study 
are presented in Figure 4.  
 
 
 
These estimated values were used during CEVI data acquisition to determine how many 
pulses can be administered and still maintain microbubble enhancement.   Baseline levels 
were found for each injection, and the time after a destruction pulse was found where the 
maximum enhancement fell below 20% of the baseline.  The number of destruction 
pulses were counted within that time and reported in Table 2.   The average number of 
destructions was four pulses with a standard deviation of two pulses. 
 
 
Figure 4. Panels a and b demonstrate two examples of multiple destructions applied to 
one slice of tissue.  The arrows indicate several examples of the applied destruction pulse 
followed by the reperfusion of the UCA. 
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TABLE 2 
Results from the Reperfusion Repeatability Study 
Mouse Injection # # of Dest. Pulses 
1 4 
1 
2 7 
1 4 
2 
2 7 
1 N/A 
3 
2 N/A 
1 N/A 
4 
2 N/A 
1 7 
5 
2 6 
1 1 
6 
2 2 
1 2 
7 
2 4 
1 5 
8 
2 4 
 
3D CEVI 
Correlation coefficients for all slices were averaged and listed for each animal in 
Table 3.   
 
TABLE 3 
Results from the CEVI and Power Doppler ROI Correlation  
Mouse 
Average r 
value 
Standard 
Deviation 
Maximum r 
value 
Minimum r 
value 
p-
value 
1 0.603 0.058 0.676 0.413 < 0.01 
2 0.535 0.086 0.674 0.372 < 0.01 
3 0.594 0.081 0.784 0.448 < 0.01 
4 0.511 0.056 0.616 0.373 < 0.01 
5 0.524 0.069 0.642 0.385 < 0.01 
6 0.508 0.085 0.665 0.285 < 0.01 
7 0.52 0.148 0.729 0.179 < 0.01 
8 0.602 0.096 0.717 0.314 < 0.01 
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By visually examining the data in a slice by slice manner, the CEVI and power Doppler 
data sets do noticeably correlate.  The results in Table 3 confirm this correlation 
indicating a mean r = 0.55 ± 0.04 (p < 0.01).   When the slices were overlaid and 
examined, such as in Figure 5, higher distributions of UCA seem to dominate the areas 
surrounding the vasculature mapped by power Doppler. 
 
 
 
In many slices, the CEVI data reveals additional vasculature or areas of higher perfusion 
that might have not been detected with power Doppler methods only.  This phenomenon 
Figure 5. Panels a-h display a slice sets from each respective mouse.  The left image in 
the set represents only the CEVI slice data while the rightmost image shows the power 
Doppler (red-blue data) overlaid on the matching CEVI slice.  While the CEVI data 
corresponds with the power Doppler data, additional CEVI signal is visible surrounding 
most of the power Doppler signal that could be the results of CEVI having a higher 
sensitivity to the microvasculature. 
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is not unexpected since CEUS is known to be more sensitive than power Doppler to 
microvasculature at the capillary level [25].  Figure 6 depicts the final reconstructed 3D 
CEVI volumes overlaid on the respective B-mode slices of each mouse.    
 
 
 
Discussion 
The mean time of UCA image enhancement found in this study corresponds to values 
previously reported in the literature [26]. This parameter provides a temporal boundary 
for application in imaging studies involving UCAs.  With a fixed 50% power applied, the 
washout curve appears reasonably consistent when repeated.  In order to optimize 
repeatability, an automated syringe pump should be used in future studies.  With an 
automated syringe pump both the amount of contrast injected as well as rate of injection 
are controlled across multiple injections and multiple subjects.   
 
Figure 5. Panels a-h demonstrate the final 3D CEVI surface rendering overlaid on 3D B-
mode slices for each mouse. A display filter isolated 80% of the signal and was applied 
such that vasculature from the skin would not be included in the 3D surface rendering.  
These 3D renderings provide spatial information about areas that are well-perfused 
within the tumor. 
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The reperfusion repeatability study provides the second essential boundary for 
developing a 3D CEVI technique.  In order to isolate only contrast enhancement, a 
baseline image must be subtracted from each slice.  This baseline image can be obtained 
by examining a slice absent of UCA; this state can be achieved by applying a destruction 
pulse.  However, with each administered destruction pulse, a certain amount of UCA, 
which varies based on the vascularity of the ROI, are destroyed from circulation.  This 
study has revealed an upper bound that is not only dependent on how long the UCA 
remains in circulation, but also how many destruction pulses can be administered until 
enhancement is not longer significant.  
Upon visual inspection of the curves produced during this study, some data sets 
appeared to lose a significant percentage of enhancement after the first pulse while other 
data sets maintained an exponential decay of signal with each administered pulse.  This 
observation could have been due to (at least) two factors.  If a section of tissue was highly 
vascularized, a larger amount of the contrast could be destroyed, thereby reducing total 
enhancement of the entire tumor region.  Another reason could be that the UCA did not 
reach steady-state in the blood stream.  Care was taken to ensure that a pulse was not 
delivered until 45 seconds after injection, but if the UCA had not fully dispersed or the 
rate of injection was varied, the destruction of a large bolus could have affected the 
maximum number of pulses allotted to a volume of data. 
The results of the 3D CEVI technique have shown potential for utilizing this 
technique for future vessel imaging related studies.  While there does exist a noticeable 
correlation between CEVI and power Doppler, correlation is limited by the inherent flaws 
in the power Doppler measurement. The strong enhancement surrounding the power 
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Doppler signal could suggest the UCAs are more sensitive to the microvasculature 
surrounding or branching from primary vessels; this attribute has been noticed in 
previous reports [25,27].  While this finding needs to be confirmed with histology, it 
suggests that power Doppler is underestimating the extent of the vasculature while UCAs 
appear to be more sensitive to the vasculature neglected by the power Doppler 
measurement. 
Multiple filters were applied to the collected data in order to isolate the contrast 
enhancement.  Intra-slice registration aided in eliminating motion artifacts.  Following 
the criteria from the reperfusion repeatability study, an intensity based filter was applied 
to the data in order to isolate all signal intensity higher than 20% of the maximum in the 
final MIP slice.  However, during data acquisition a visual estimation of the number of 
destruction pulses allotted to one injection was found to be ~ 10 pulses.  Only after 
quantitative analysis was this value found to be grossly overestimated, so slices imaged 
after the maximum number of destruction pulses may have lost significant contrast.  This 
inherent issue might have increased the amount of signal being filtered during post-
processing.  Another filter was applied to eliminate spurious artifacts due to speckle.  
UCAs rapidly enhance intensity; so, by eliminating pixels that do not significantly 
change over time, other motion or speckle artifacts are removed.  Finally, a filter was 
applied that isolated groups of enhancing pixels.   
Automated rigid registration between the final volume sets provided a voxel by voxel 
comparison of the two data sets.  However, interpolation between slices as well as errors 
during manual incremental stepping in the CEVI technique required adjustment of initial 
parameters, making the applied registration semi-automated.  Utilizing a motor with a 
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fixed step size in future studies would eliminate registration issues due to errors in 
stepping between slices.  
While this work demonstrates promising preliminary results, limitations in this study 
require future work.  Refining methods of isolating the ultrasound contrast signal is 
necessary to provide more quantifiable results.  Tracking the change in intensity not just 
temporally but spatially may provide very specific borders within the microvasculature. 
In addition, further studies are needed to validate this technique to other accepted 
angiography methods such as MRA or CT.  Since UCAs can be targeted to specific 
intravascular receptors, this approach could be applied in constructing 3D representations 
of receptor distribution to further elucidate other molecular properties of the tumor 
involved in cancer progression [26,28]. 
To the best of our knowledge, the 3D CEVI approach presented here is the first 
attempt at a high resolution 3D vessel imaging technique using ultrasound contrast 
agents.  This method provides a fast and accessible way of determining the progression of 
tumor growth or therapeutic efficacy of anti-angiogenic drugs.  In addition, this technique 
allows ultrasound to become a 3D molecular imaging modality with the use of targeted 
ultrasound contrast agents.  These advances presented further enable ultrasound to move 
from a structural imaging technique to a functional and molecular approach for 
quantitative cancer imaging.  
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CHAPTER III 
 
REPEATABILITY OF BLOOD FLOW MODELING USING CONTRAST 
ENHANCED SONOGRAPHY 
 
Introduction 
The quantification of tissue function has become an important element in assessing 
tumor growth and cancer treatment efficacy.  As treatments target specific aspects of the 
cancer, qualitative evaluation is no longer adequate in determining the value of a 
treatment option.  For example, methods are needed to assess blood flow and tissue 
perfusion for drugs that target the tumor vasculature (i.e., anti-angiogenic treatments).  
Contrast agents have been used to exploit functional elements of the tumor milieu such as 
blood flow, pH, and matrix metalloprotease (MMP) activity in an array of different 
imaging modalities [29-36].  Some parameters, such as blood flow, have been measured 
using multiple modalities, including CEUS [17].  Relative to the other methods such as 
dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) or contrast 
enhanced computed tomography (CT), CEUS presents a fast, cost effective, and safe 
option.   
While many models exploit the kinetic behavior of UCAs  to extract information 
about blood flow and vascularity, the model used in this study has been modified to 
examine blood flow in high frequency, high resolution CEUS [37].  High resolution 
CEUS has a lower signal to noise per voxel due to less UCA within an ROI.  Therefore, 
TICs obtained from high resolution CEUS tend to be noisy and difficult to fit accurately.  
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Described below is the model used in this study; a more detailed description is available 
by Yeh, et al [37]. 
Adapted from Wei, et al [17], the reperfusion curve can be fit to a mono-exponential 
model described previously: 
                                                    )1)(()( teABAtR β−−−+= ,                           (Equation 4) 
where A represents intensity immediately after the destruction pulse (background 
intensity), B represents the steady-state intensity after contrast equilibration and β is a rate 
constant proportional to contrast velocity.  If the image obtained immediately after the 
destruction pulse is subtracted from the subsequent reperfusion images, 
0=A  
so that 
                                                          )1(*)( teBtR β−−= .                                (Equation 5) 
In order to reduce parametric sensitivity to local noise error, a running average of the 
time intensity curve is utilized by integrating both sides and dividing by the time: 
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      (Equation 6) 
For each pixel, the integrative TIC (ITIC) can be fit to Equation 6 to form maps of β, B, 
and β·B, the latter has been shown to indicate blood flow [17,37].  For multiple 
destruction pulses on the same section of tissue, the β maps are expected to be equal until 
the UCA is destroyed and intensity returns to baseline.  This study presents preliminary 
results regarding the repeatability of β measures for approximately five pulses produced 
from two separate injections in six mice. 
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Materials and Methods 
Data Acquisition 
All procedures adhered to our Institution’s Animal Care and Use Committee 
guidelines.  Eight female mice were injected subcutaneously with 10
6
 67NR breast cancer 
cells in the hind limb.  Eight days postinjection, they were imaged on a Visualsonics 
Vevo 770 (Toronto, Canada) system using a 30 MHz transducer mounted to a 3D motor 
on a rail system.  Two days prior to imaging, jugular catheters were surgically implanted 
for delivery of the contrast agent. During the imaging session, the animals were 
anesthetized with a 2%/98% isoflurane/oxygen mixture, and body temperature was 
monitored and maintained at 37
o
 C by a warming plate.  Heart rate was also monitored 
and remained approximately 350 – 400 bpm.   
Coupling gel was applied to the area of interest, and 2D B-mode and power Doppler 
scout images established a slice of tumor with moderate vascularity.  The field of view 
varied from 9 mm X 9 mm to 12 mm X 12 mm depending on tumor size, establishing an 
in plane pixel size of less than or equal to ~25 µm X 25 µm.  Image acquisition began 
immediately prior to a 50 µl bolus of Visualsonics Micromarker microbubbles injected 
via a jugular catheter.  These microbubbles are specifically designed for high frequency 
(30 – 45 MHz) ultrasound imaging, and the diameter of the microbubbles range from 2 to 
3 µm.  Once the 50 µl bolus of Visualsonics Micromarker microbubbles injected reached 
steady state (approximately 45 seconds) [11,27], imaging began using the Visualsonics 
Contrast mode at a frame rate of 14 frames/second at 50% power (mechanical index 
(M.I.) of 0.14) .  A 100% power destruction pulse (M.I. of 0.59) was administered, and 
images were collected for approximately 15-20 seconds in order to characterize the 
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reperfusion curve.  Twelve to eighteen sets of reperfusion images were collected using 
multiple destruction pulses over ten minutes.  This process was then repeated for each 
subject after a 30 minute period of time to allow for clearance of residual contrast agent. 
 
Data Analysis 
From a previous study, it was found that approximately four ± two destruction pulses 
can be administered before the enhancement due to the UCA becomes insignificant.  
Using this finding as a guide, five sets of reperfusion data from each mouse and each 
injection were used to examine the repeatability of the parameters produced from 
Equation 6.  Using the Visualsonics (Toronto, Canada) Vevo 770 software, ROIs were 
manually drawn around the entire tumor and TICs were exported to Matlab (The 
Mathworks, Natick, MA, USA) for each injection on each mouse.  A Matlab algorithm fit 
the data to Equation 6 using the command lsqcurvefit.  Fit parameters were then 
exported to Matlab for statistical analysis. 
For each injection for each mouse, B and β were plotted for five destruction pulses.  
The five β measurements were averaged for each injection for each subject, and Bland 
Altman plots were created using the differences between the averages for each injection 
[38].  
   
Results 
Plots of both the B and β parameters, as in Figures 7 and 8, reveal significant 
variation between subsequent destruction pulses.  B appears to rely on the concentration 
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of the UCA in circulation and was not tested for repeatability. However, it is noted that it 
follows the general exponential decay of UCA seen in the Figure 3.   
 
 
 
The β parameter was plotted and assessed for repeatability, and a Bland Altman plot is 
shown in Figure 9.   
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Figure 7. Five B parameters for one mouse with panel a shows the measurements for 
injection 1 while panel b plots injection 2.  The error bars represent 1 standard deviation. 
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Figure 8. Five β parameters for one mouse with panel a showing the measurements for 
injection 1 while panel b plots injection 2.  The dotted line represents the mean β value 
for the sample while the error bars represent 1 standard deviation of error.   
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a b 
 28 
The mean difference between the average β for each injection was found to be 0.061 ± 
0.2980.  The 95% lines of agreement fall on 0.656 and -0.536; thus, differences between 
injections for each animal would be expected to fall between these values with 95% 
confidence 
. 
 
 
Discussion 
Upon initial interrogation into the variation among subsequent fit parameters, it was 
concluded that a repeatability assessment of the model must be performed.  Theory 
regarding the model suggests that the β parameter, proportional to contrast velocity, 
Figure 9. Bland Altman plot of the six mice. The dotted line represents the mean 
difference between injections on the same animal while the solid lines represent the 95% 
confidence interval.  
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should change minimally throughout multiple destruction pulses.  Although more 
subjects are needed to conclude the threshold for inter-/intra-subject error over repeated 
measurements, it is clear by the 95% range in Figure 9 that the β parameter seems to have 
a greater fluctuation than anticipated for multiple measurements of the same section of 
tissue.   
Some of the variation could be due to errors during acquisition.  The UCA was 
injected via a jugular catheter manually over a 15 second interval and 45 seconds elapsed 
until the first destruction in order for the UCA to reach equilibrium in circulation.  
However, an automated syringe could have facilitated a more constant infusion rate, 
leading to a higher probability of the UCA reaching steady-state after the 45 second 
period of time post-injection.  If steady state was not reached, a bolus of UCA could have 
been problematic when fitting to a model that assumes uniform distribution; thus, false or 
incorrect fit parameters could have introduced error in this study.  As discussed 
previously, contrast-enhanced high frequency ultrasound imaging suffers from a lower 
signal to noise ratio (SNR).  This lower SNR reflects less CA per voxel because of the 
increased spatial resolution.  While using a model that eliminates much of the noise by 
integrating the signal over time provides better model fits, we can not assume that noise 
does not affect the output parameters.  Thus, the low SNR could also affect the 
discrepancies in parametric repeatability. Tumor vasculature is inherently leaky and 
poorly constructed.  These physiological variations could contribute to the disparity in 
parameter measurements as well. 
This study has shown the preliminary findings that suggest poor repeatability of a 
clinically accepted method of blood flow modeling.  In future studies, six more mice will 
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be incorporated into this study in order to determine a more adequate assessment.  
Further analysis will be used to determine the sources for any differences in kinetic 
modeling of the tumor microvasculature using high-resolution US imaging. 
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CHAPTER IV 
 
CONCLUSIONS 
 
This thesis has demonstrated a novel technique in monitoring tumor growth and anti-
angiogenic cancer treatments.  High resolution contrast enhanced vessel imaging is safe 
and cost-effective alternative to other 3D angiography techniques and provides higher 
sensitivity about vascularity and perfusion than current ultrasound blood flow measures.   
While this technique shows promise, some limitations require additional study. 
First and foremost, methods in UCA tracking must be explored.  Current filtering 
techniques need to be expanded to include a tracking algorithm that will examine both 
temporal and spatial changes in image intensity to further determine the UCA patterns.  
Developing a technique such as UCA tracking could provide better boundaries for 
microvasculature and reduce artifacts from motion.   
The development of targeted microbubbles enables ultrasound to provide information 
about a region of tissue on a molecular level.  For example, by targeting UCAs to VEGF 
receptors 1 and 2 (VEGF R1 and VEGF R2), molecular information can be obtained 
regarding the distribution of these receptors within tumors.  This 2D methodology has 
been used to examine the efficacy of antiangiogenic and cytotoxic drugs in pancreatic 
cancer mouse models [39-40].  However, by using similar techniques as the 3D CEVI 
technique described, 3D molecular imaging can be achieved using ultrasound.  3D 
information regarding VEGF receptor distribution could not only provide additional 
insight to monitoring tumor growth and cancer treatments, but could also be integrated 
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into multi-parametric studies to assess many aspects of the same tumor over a long period 
of time.   
In addition, preliminary results from the repeatability study of the commonly used 
mono-exponential model show greater change in values than anticipated.  While more 
subjects are necessary to absolutely conclude the repeatability of this model, these initial 
findings allude to re-examination of the model when measuring microvascular blood 
flow. 
This study has provided a reasonable alternative to other methods of angiography as 
well as a potential method for creating 3D representations of endothelial proteins; thus 
ultrasound has become a candidate for multi-modal and multi-parametric studies of the 
tumor microenvironment.   
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APPENDIX 
 
ADDITIONAL FIGURES 
 
Duration of UCA Enhancement plots for the 7 other subjects.  
 
 
 
 
Figure 10.  Time intensity curves from the duration of UCA enhancement study for 
Mouse 1. Panel a demonstrates the entire pre- and post-injection TIC with the 
highlighted region that was compared in panel b. The linearity seen in panel b depicts 
the repeatability of the washout curve. 
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Figure 12.  Time intensity curves from the duration of UCA enhancement study for 
Mouse 4. Panel a demonstrates the entire pre- and post-injection TIC with the 
highlighted region that was compared in panel b. The linearity seen in panel b depicts 
the repeatability of the washout curve. 
 
 
Figure 11.  Time intensity curves from the duration of UCA enhancement study for 
Mouse 3. Panel a demonstrates the entire pre- and post-injection TIC with the 
highlighted region that was compared in panel b. The linearity seen in panel b depicts 
the repeatability of the washout curve. 
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Figure 14.  Time intensity curves from the duration of UCA enhancement study for 
Mouse 6. Panel a demonstrates the entire pre- and post-injection TIC with the 
highlighted region that was compared in panel b. The linearity seen in panel b depicts 
the repeatability of the washout curve. 
 
 
Figure 13.  Time intensity curves from the duration of UCA enhancement study for 
Mouse 5. Panel a demonstrates the entire pre- and post-injection TIC with the 
highlighted region that was compared in panel b. The linearity seen in panel b depicts 
the repeatability of the washout curve. 
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Figure 16.  Time intensity curves from the duration of UCA enhancement study for 
Mouse 8. Panel a demonstrates the entire pre- and post-injection TIC with the 
highlighted region that was compared in panel b. The linearity seen in panel b depicts 
the repeatability of the washout curve. 
 
 
Figure 15.  Time intensity curves from the duration of UCA enhancement study for 
Mouse 7. Panel a demonstrates the entire pre- and post-injection TIC with the 
highlighted region that was compared in panel b. The linearity seen in panel b depicts 
the repeatability of the washout curve. 
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Reperfusion repeatability plots for the 6 other subjects; however, mouse 3 was not used 
in study due to the lack of UCA enhancement and the data taken from mouse 4 was 
corrupted.  
 
 
 
 
 
 
Figure 17.  Time intensity curves from the reperfusion repeatability study for Mouse 1. 
Multiple destruction pulses were administered followed by imaging of the reperfusion 
of the contrast into the field of view.  These figures show the intensity of the image 
increases after the destruction pulse destroyed all contrast. 
 
 
Figure 18.  Time intensity curves from the reperfusion repeatability study for Mouse 3. 
Multiple destruction pulses were administered followed by imaging of the reperfusion 
of the contrast into the field of view.  These figures show the intensity of the image 
increases after the destruction pulse destroyed all contrast. 
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Figure 20.  Time intensity curves from the reperfusion repeatability study for Mouse 6. 
Multiple destruction pulses were administered followed by imaging of the reperfusion 
of the contrast into the field of view.  These figures show the intensity of the image 
increases after the destruction pulse destroyed all contrast. 
 
 
Figure 19.  Time intensity curves from the reperfusion repeatability study for Mouse 5. 
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Figure 22.  Time intensity curves from the reperfusion repeatability study for Mouse 8. 
Multiple destruction pulses were administered followed by imaging of the reperfusion 
of the contrast into the field of view.  These figures show the intensity of the image 
increases after the destruction pulse destroyed all contrast. 
 
 
Figure 21.  Time intensity curves from the reperfusion repeatability study for Mouse 7. 
Multiple destruction pulses were administered followed by imaging of the reperfusion 
of the contrast into the field of view.  These figures show the intensity of the image 
increases after the destruction pulse destroyed all contrast. 
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Additional plots of the kinetic parameters derived from the blood flow modeling. 
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Figure 23.  Five β measurements for each injection on mice 1-3. Error bars represent 1 
standard deviation while the dotted line is the β value. 
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Figure 24.  Five β measurements for each injection on mice 4-6. Error bars represent 1 
standard deviation while the dotted line is the β value. 
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Figure 25.  Five B measurements for each injection on mice 1-3. Error bars represent 1 
standard deviation. 
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Figure 26.  Five B measurements for each injection on mice 4-6. Error bars represent 1 
standard deviation. 
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